Merck's heart failure drug misses trial goals

Jun 05, 2009

(AP) -- Merck and Co. said Friday its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.

The company said rolofylline did not reach its primary or secondary goals in the late-stage trial. Based on the results, Merck said it no longer plans to ask the to approve the drug candidate this year.

The trial also showed that 30 mg of rolofylline did not reduce the risk of death or hospitalization due to heart or kidney problems 60 days after treatment, and that it did not reduce kidney impairment.

Merck is still analyzing study data from the study, which is called PROTECT, and it will present full results from the 2,033-patient trial at a medical conference later this year.

In morning trading, Merck shares fell 64 cents, or 2.4 percent, to $25.94.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Italy bans Novartis flu vaccine after suspicious deaths

add to favorites email to friend print save as pdf

Related Stories

FDA to review Vytorin results

Jan 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

AstraZeneca, Merck collaborate on cancer treatment

Jun 01, 2009

(AP) -- AstraZeneca PLC and Merck & Co. said Monday they will jointly develop a pair of drugs meant to hit cancer with a one-two punch, part of a growing trend of combination cancer treatments.

Trials find no benefits of Zetia

Jan 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

Study: Vioxx poses even short-term risks

May 03, 2006

A Montreal study raises questions about even short-term use of the pain drug Vioxx and may harm Merck & Co.'s defense against 11,500 lawsuits, a report said.

FDA pans Merck's new pain pill

Apr 13, 2007

The U.S. Food and Drug Administration has rejected Merck's bid to sell the pain medication Arcoxia in the United States.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
1 / 5 (1) Jun 05, 2009
Did the silly study name reflect the outcome for the patients or the bottom line.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.